OnKure Therapeutics, Inc. (OKUR)
NASDAQ: OKUR · Real-Time Price · USD
2.400
+0.400 (20.00%)
At close: Aug 13, 2025, 4:00 PM
2.360
-0.040 (-1.67%)
Pre-market: Aug 14, 2025, 8:00 AM EDT

OnKure Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22
Selling, General & Admin
13.2110.374.823.9
Research & Development
49.4843.1732.1225.86
Operating Expenses
62.6953.5436.9329.77
Operating Income
-62.69-53.54-36.93-29.77
Interest Expense
-0.12-0.15--
Interest & Investment Income
3.52.011.620.25
Other Non Operating Income (Expenses)
-0.04-0.04--
EBT Excluding Unusual Items
-59.35-51.71-35.31-29.51
Merger & Restructuring Charges
-0.23-0.23--
Other Unusual Items
-0.74-0.74--
Pretax Income
-60.31-52.67-35.31-29.51
Net Income
-60.31-52.67-35.31-29.51
Net Income to Common
-60.31-52.67-35.31-29.51
Shares Outstanding (Basic)
1030-
Shares Outstanding (Diluted)
1030-
Shares Change (YoY)
-25.13%1114.54%--
EPS (Basic)
-6.02-15.28-124.41-
EPS (Diluted)
-6.02-15.28-124.41-
Free Cash Flow
-61.36-51.17-34.79-28.09
Free Cash Flow Per Share
-6.12-14.84-122.59-
EBITDA
-62.22-53.08-36.52-29.54
D&A For EBITDA
0.470.460.420.23
EBIT
-62.69-53.54-36.93-29.77
Updated Mar 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q